A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach
<b>Background/Objective:</b> Sacubitril/Valsartan are a combination drug approved for heart failure treatment, known to enhance natriuretic peptide activity and inhibit the renin–angiotensin–aldosterone system (RAAS). While its clinical efficacy is well-established, its broader impact on human metab...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2025-08-01
|
| Rangatū: | Pharmaceuticals |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/1424-8247/18/9/1264 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|